{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:31:06Z","timestamp":1769067066808,"version":"3.49.0"},"reference-count":71,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,7,28]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Notwithstanding important advances in the treatment of epithelial ovarian cancer (EOC),\nthis disease is still a leading cause of global high mortality from gynecological malignancies. Recurrence\nin EOC is inevitable and it is responsible for poor survival rates. There is a critical need for novel\neffective biomarkers with improved accuracy compared to the standard carbohydrate antigen-125\n(CA-125) for follow-up. The human epididymis protein 4 (HE4) is used for early detection of EOC\n(ROMA algorithm) as well as for predicting optimal cytoreduction after neoadjuvant chemotherapy\nand survival outcomes. Notably, the emerging HE4 is a promising prognostic biomarker that has displayed\nbetter accuracy in various recent studies for detecting recurrent disease. In this mini-review, we\ndiscussed the potential of HE4 as an accurate predictor of EOC recurrence.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666200425211732","type":"journal-article","created":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T06:34:36Z","timestamp":1587882876000},"page":"1026-1033","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8414-4145","authenticated-orcid":true,"given":"Khalid","family":"El Bairi","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohamed Ist University, Oujda, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Afqir","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohamed Ist University, Oujda, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Amrani","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","volume":"41","author":"Webb,PM.","year":"2017","unstructured":"Webb,PM.; Jordan,SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017; 41: 3-14. http:\/\/dx.doi.org\/10.1016\/j.bpobgyn.2016.08.006 PMID: 27743768","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref=2","author":"Bray,F.","unstructured":"Bray,F.; Ferlay,J.; Soerjomataram,I.; Siegel,RL.; Torre,LA.; Jemal,A. Global cancer statistics. 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14737159.2017.1326820","volume":"17(6)","author":"Yang,WL.","year":"2017","unstructured":"Yang,WL.; Lu,Z.; Bast,RC,Jr. The role of biomarkers in the ma-nagement of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017; 17(6): 577-91. http:\/\/dx.doi.org\/10.1080\/14737159.2017.1326820 PMID: 28468520","journal-title":"Expert Rev Mol Diagn"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s13402-016-0309-1","volume":"40(2)","author":"El,Bairi,K.","year":"2017a","unstructured":"El Bairi K, Kandhro AH, Gouri A.;et al. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. Cell On-col (Dordr). 2017a; 40(2): 105-18. http:\/\/dx.doi.org\/10.1007\/s13402-016-0309-1 PMID: 27981507","journal-title":"Cell On-col (Dordr)"},{"key":"ref=5","first-page":"163","volume":"34(2)","author":"Qiao,N.","year":"2013","unstructured":"Qiao,N.; Li,H. The value of mesothelin in the diagnosis and follow-up of surgically treated ovarian cancer. Eur J Gynaecol Oncol. 2013; 34(2): 163-5. PMID: 23781590","journal-title":"Eur J Gynaecol Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13048-017-0369-5","volume":"10(1)","author":"Cheng,X.","year":"2017","unstructured":"Cheng,X.; Zhang,L.; Chen,Y.; Qing,C. Circulating cell-free DNA and circulating tumor cells, the \u201cliquid biopsies\u201d in ovarian cancer. J Ovarian Res. 2017; 10(1): 75. http:\/\/dx.doi.org\/10.1186\/s13048-017-0369-5 PMID: 29132396","journal-title":"J Ovarian Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ygyno.2018.08.025","volume":"151(1)","author":"Lycke,M.","year":"2018","unstructured":"Lycke,M.; Kristjansdottir,B.; Sundfeldt,K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol On-col. 2018; 151(1): 159-65. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2018.08.025 PMID: 30149898","journal-title":"Gynecol On-col"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/CEJ.0000000000000259","volume":"26(4)","author":"Zapardiel,I.","year":"2017","unstructured":"Zapardiel,I.; Gorostidi,M.; Ravaggi,A.; Allende,MT.; Silveira,M.; Macuks,R. Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study. Eur J Cancer Prev. 2017; 26(4): 346-50. http:\/\/dx.doi.org\/10.1097\/CEJ.0000000000000259 PMID: 27116243","journal-title":"Eur J Cancer Prev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00404-020-05447-z","volume":"301(3)","author":"Mi,D.","year":"2020","unstructured":"Mi,D.; Zhang,Y. Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma. Arch Gynecol Obstet. 2020; 301(3): 779-85. http:\/\/dx.doi.org\/10.1007\/s00404-020-05447-z PMID: 32034508","journal-title":"Arch Gynecol Obstet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ygyno.2016.01.016","volume":"141(2)","author":"Romagnolo,C.","year":"2016","unstructured":"Romagnolo C, Leon AE, Fabricio ASC.;et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA)  as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicen-ter study. Gynecol Oncol. 2016; 141(2): 303-11. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2016.01.016 PMID: 26801941","journal-title":"Gynecol Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047672","author":"Chhikara,N.","unstructured":"Chhikara,N.; Saraswat,M.; Tomar,AK.; Dey,S.; Singh,S.; Yadav,S. Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor. PLoS One. 2012; 7(11) e47672 http:\/\/dx.doi.org\/10.1371\/journal.pone.0047672 PMID: 23139753","journal-title":"PLoS One"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/modpathol.3800612","volume":"19(6)","author":"Galgano,MT.","year":"2006","unstructured":"Galgano,MT.; Hampton,GM.; Frierson,HF,Jr. Comprehensive analy-sis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19(6): 847-53. http:\/\/dx.doi.org\/10.1038\/modpathol.3800612 PMID: 16607372","journal-title":"Mod Pathol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.18632\/oncotarget.6327","volume":"7(1)","author":"Zhu,L.","year":"2016","unstructured":"Zhu L, Zhuang H, Wang H.;et al. Overexpression of HE4 (human epididymis protein 4)  enhances proliferation, invasion and meta-stasis of ovarian cancer. Oncotarget. 2016; 7(1): 729-44. http:\/\/dx.doi.org\/10.18632\/oncotarget.6327 PMID: 26575020","journal-title":"Oncotarget"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan2507","author":"Uhlen,M.","unstructured":"Uhlen M, Zhang C, Lee S.;et al. A pathology atlas of the human cancer transcriptome. Science. 2017; 357(6352) eaan2507 http:\/\/dx.doi.org\/10.1126\/science.aan2507 PMID: 28818916","journal-title":"Science"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1530\/ERC-11-0329","volume":"19(2)","author":"Gyorffy,B.","year":"2012","unstructured":"Gyorffy,B.; L\u00e1nczky,A.; Sz\u00e1ll\u00e1si,Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ova-rian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012; 19(2): 197-208. http:\/\/dx.doi.org\/10.1530\/ERC-11-0329 PMID: 22277193","journal-title":"Endocr Relat Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ijc.32369","volume":"145(11)","author":"Fekete,JT.","year":"2019","unstructured":"Fekete,JT.; Gyorffy,B. ROCplot.org: Validating predictive biomar-kers of chemotherapy\/hormonal therapy\/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients. Int J Cancer. 2019; 145(11): 3140-51. http:\/\/dx.doi.org\/10.1002\/ijc.32369 PMID: 31020993","journal-title":"Int J Cancer"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1465-9921-7-61","volume":"7(1)","author":"Bingle,L.","year":"2006","unstructured":"Bingle L, Cross SS, High AS.;et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006; 7(1): 61. http:\/\/dx.doi.org\/10.1186\/1465-9921-7-61 PMID: 16600032","journal-title":"Respir Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1177\/1933719113503416","volume":"21(4)","author":"Orfanelli,T.","year":"2014","unstructured":"Orfanelli,T.; Jayaram,A.; Doulaveris,G.; Forney,LJ.; Ledger,WJ.; Witkin,SS. Human epididymis protein 4 and secretory leukocyte protease inhibitor in vaginal fluid: relation to vaginal components and bacterial composition. Reprod Sci. 2014; 21(4): 538-42. http:\/\/dx.doi.org\/10.1177\/1933719113503416 PMID: 24023032","journal-title":"Reprod Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/srep03574","volume":"4","author":"Moore,RG.","year":"2014","unstructured":"Moore RG, Hill EK, Horan T.;et al. HE4 (WFDC2)  gene overex-pression promotes ovarian tumor growth. Sci Rep. 2014; 4: 3574. http:\/\/dx.doi.org\/10.1038\/srep03574 PMID: 24389815","journal-title":"Sci Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fonc.2018.00124","volume":"8","author":"James,NE.","year":"2018","unstructured":"James,NE.; Chichester,C.; Ribeiro,JR. Beyond the Biomarker: Un-derstanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer. Front Oncol. 2018; 8: 124. http:\/\/dx.doi.org\/10.3389\/fonc.2018.00124 PMID: 29740539","journal-title":"Front Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbrc.2012.02.008","volume":"419(2)","author":"Lu,R.","year":"2012","unstructured":"Lu,R.; Sun,X.; Xiao,R.; Zhou,L.; Gao,X.; Guo,L. Human epididymis protein 4 (HE4)  plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun. 2012; 419(2): 274-80. http:\/\/dx.doi.org\/10.1016\/j.bbrc.2012.02.008 PMID: 22342977","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/1476-4598-13-243","volume":"13","author":"Zhuang,H.","year":"2014","unstructured":"Zhuang H, Tan M, Liu J.;et al. Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells. Mol Cancer. 2014; 13: 243. http:\/\/dx.doi.org\/10.1186\/1476-4598-13-243 PMID: 25362534","journal-title":"Mol Cancer"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1080\/14737159.2016.1251317","volume":"16(12)","author":"Qu,W.","year":"2016","unstructured":"Qu W, Li J, Duan P.;et al. Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies. Expert Rev Mol Diagn. 2016; 16(12): 1271-82. http:\/\/dx.doi.org\/10.1080\/14737159.2016.1251317 PMID: 27784171","journal-title":"Expert Rev Mol Diagn"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0378-1119(99) 00342-X","volume":"238(2)","author":"Schummer,M.","year":"1999","unstructured":"Schummer M, Ng WV, Bumgarner RE.;et al. Comparative hybri-dization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999; 238(2): 375-85. http:\/\/dx.doi.org\/10.1016\/S0378-1119(99) 00342-X PMID: 10570965","journal-title":"Gene"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/PGP.0b013e31824fe269","volume":"31(6)","author":"Georgakopoulos,P.","year":"2012","unstructured":"Georgakopoulos,P.; Mehmood,S.; Akalin,A.; Shroyer,KR. Immuno-histochemical localization of HE4 in benign, borderline, and ma-lignant lesions of the ovary. Int J Gynecol Pathol. 2012; 31(6): 517-23. http:\/\/dx.doi.org\/10.1097\/PGP.0b013e31824fe269 PMID: 23018214","journal-title":"Int J Gynecol Pathol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65(6)","author":"Drapkin,R.","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y.;et al. Human epididymis pro-tein 4 (HE4)  is a secreted glycoprotein that is overexpressed by se-rous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6): 2162-9. http:\/\/dx.doi.org\/10.1158\/0008-5472.CAN-04-3924 PMID: 15781627","journal-title":"Cancer Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jog.13181","volume":"43(1)","author":"Lee,S.","year":"2017","unstructured":"Lee,S.; Choi,S.; Lee,Y.; Chung,D.; Hong,S.; Park,N. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer. J Obstet Gynaecol Res. 2017; 43(1): 220-7. http:\/\/dx.doi.org\/10.1111\/jog.13181 PMID: 27862665","journal-title":"J Obstet Gynaecol Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3892\/or.2014.3549","volume":"33(1)","author":"Wang,H.","year":"2015","unstructured":"Wang,H.; Zhu,L.; Gao,J.; Hu,Z.; Lin,B. Promotive role of recombi-nant HE4 protein in proliferation and carboplatin resistance in ova-rian cancer cells. Oncol Rep. 2015; 33(1): 403-12. http:\/\/dx.doi.org\/10.3892\/or.2014.3549 PMID: 25354091","journal-title":"Oncol Rep"},{"key":"ref=29","author":"El,Bairi,K.","unstructured":"El Bairi,K.; Amrani,M.; Kandhro,AH.; Afqir,S. Prediction of therapy response in ovarian cancer: Where are we now? Crit Rev Clin Lab Sci 2017b; 54(4): 233-66. http:\/\/dx.doi.org\/10.1080\/10408363.2017.1313190 PMID: 28443762."},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13048-016-0240-0","volume":"9(1)","author":"Ribeiro,JR.","year":"2016","unstructured":"Ribeiro JR, Schorl C, Yano N.;et al. HE4 promotes collateral re-sistance to cisplatin and paclitaxel in ovarian cancer cells. J Ovari-an Res. 2016; 9(1): 28. http:\/\/dx.doi.org\/10.1186\/s13048-016-0240-0 PMID: 27184254","journal-title":"J Ovari-an Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023","volume":"128(2)","author":"Braicu,EI.","year":"2013","unstructured":"Braicu EI, Fotopoulou C, Van Gorp T.;et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013; 128(2): 245-51. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2012.11.023 PMID: 23178313","journal-title":"Gynecol Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"14765","DOI":"10.1007\/s13277-016-5335-0","volume":"37(11)","author":"Shen,Y.","year":"2016","unstructured":"Shen,Y.; Li,L. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. Tumour Biol. 2016; 37(11): 14765-72. http:\/\/dx.doi.org\/10.1007\/s13277-016-5335-0 PMID: 27629144","journal-title":"Tumour Biol"},{"key":"ref=33","author":"Aarenstrup,Karlsen,M.","unstructured":"Aarenstrup Karlsen M, H\u00f8gdall C, Nedergaard L.;et al. HE4 as a predictor of adjuvant chemotherapy resistance and survival in pati-ents with epithelial ovarian cancer. APMIS 2016; 124(12): 1038-45. http:\/\/dx.doi.org\/10.1111\/apm.12625 PMID: 27859687","journal-title":"APMIS"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","volume":"17(9)","author":"Scaletta,G.","year":"2017","unstructured":"Scaletta G, Plotti F, Luvero D.;et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev Anticancer Ther. 2017; 17(9): 827-39. http:\/\/dx.doi.org\/10.1080\/14737140.2017.1360138 PMID: 28756722","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14737159.2018.1457436","volume":"18(4)","author":"Cao,H.","year":"2018","unstructured":"Cao,H.; You,D.; Lan,Z.; Ye,H.; Hou,M.; Xi,M. Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies. Expert Rev Mol Diagn. 2018; 18(4): 371-83. http:\/\/dx.doi.org\/10.1080\/14737159.2018.1457436 PMID: 29569984","journal-title":"Expert Rev Mol Diagn"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.2147\/CMAR.S178345","volume":"10","author":"Dai,C.","year":"2018","unstructured":"Dai C, Zheng Y, Li Y.;et al. Prognostic values of HE4 expression in patients with cancer: a meta-analysis. Cancer Manag Res. 2018; 10: 4491-500. http:\/\/dx.doi.org\/10.2147\/CMAR.S178345 PMID: 30349381","journal-title":"Cancer Manag Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1097\/IGC.0b013e3182681cfd","volume":"22(9)","author":"Steffensen,KD.","year":"2012","unstructured":"Steffensen,KD.; Waldstr\u00f8m,M.; Brandslund,I.; Petzold,M.; Jakobsen,A. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. Int J Gynecol Cancer. 2012; 22(9): 1474-82. http:\/\/dx.doi.org\/10.1097\/IGC.0b013e3182681cfd PMID: 23095772","journal-title":"Int J Gynecol Cancer"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1095\/biolreprod45.2.350","volume":"45(2)","author":"Kirchhoff,C.","year":"1991","unstructured":"Kirchhoff,C.; Habben,I.; Ivell,R.; Krull,N. A major human epididy-mis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991; 45(2): 350-7. http:\/\/dx.doi.org\/10.1095\/biolreprod45.2.350 PMID: 1686187","journal-title":"Biol Reprod"},{"key":"ref=39","doi-asserted-by":"publisher","author":"Plotti,F.","unstructured":"Plotti F, Guzzo F, Schir\u00f2 T.;et al. Role of human epididymis pro-tein 4 (HE4)  in detecting recurrence in CA125 negative ovarian cancer patients [published online ahead of print. 2019 Apr 16]. Int J Gynecol Cancer 2019. http:\/\/dx.doi.org\/10.1136\/ijgc-2019-000211","DOI":"10.1136\/ijgc-2019-000211"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clinbiochem.2018.08.003","volume":"60","author":"Ferraro,S.","year":"2018","unstructured":"Ferraro,S.; Robbiano,C.; Tosca,N.; Panzeri,A.; Paganoni,AM.; Pan-teghini,M. Serum human epididymis protein 4 vs. carbohydrate an-tigen 125 in ovarian cancer follow-up. Clin Biochem. 2018; 60: 84-90. http:\/\/dx.doi.org\/10.1016\/j.clinbiochem.2018.08.003 PMID: 30125544","journal-title":".Clin Biochem"},{"key":"ref=41","first-page":"4483","volume":"17(9)","author":"Innao,P.","year":"2016","unstructured":"Innao,P.; Pothisuwan,M.; Pengsa,P. Does Human Epididymis Pro-tein 4 (HE4)  Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer. Asian Pac J Cancer Prev. 2016; 17(9): 4483-6. PMID: 27797265","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s13277-015-4031-9","volume":"37(3)","author":"Nassir,M.","year":"2016","unstructured":"Nassir M, Guan J, Luketina H.;et al. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. Tumour Biol. 2016; 37(3): 3009-16. http:\/\/dx.doi.org\/10.1007\/s13277-015-4031-9 PMID: 26419591","journal-title":"Tumour Biol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.3892\/or.2013.2682","volume":"30(5)","author":"Manganaro,L.","year":"2013","unstructured":"Manganaro L, Michienzi S, Vinci V.;et al. Serum HE4 levels com-bined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep. 2013; 30(5): 2481-7. http:\/\/dx.doi.org\/10.3892\/or.2013.2682 PMID: 23970060","journal-title":"Oncol Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ygyno.2011.11.050","volume":"125(1)","author":"Schummer,M.","year":"2012","unstructured":"Schummer M, Drescher C, Forrest R.;et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by compa-rison to the established marker CA125. Gynecol Oncol. 2012; 125(1): 65-9. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2011.11.050 PMID: 22155417","journal-title":"Gynecol Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s13277-012-0381-8","volume":"33(5)","author":"Granato,T.","year":"2012","unstructured":"Granato,T.; Midulla,C.; Longo,F.; Colaprisca,B.; Frati,L.; Anastasi,E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol. 2012; 33(5): 1335-9. http:\/\/dx.doi.org\/10.1007\/s13277-012-0381-8 PMID: 22528938","journal-title":"Tumour Biol"},{"key":"ref=46","doi-asserted-by":"publisher","author":"Plotti,F.","unstructured":"Plotti F, Capriglione S, Terranova C.;et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012; 33(6): 2117-23. http:\/\/dx.doi.org\/10.1007\/s13277-012-0471-7 PMID: 22875782","DOI":"10.1007\/s13277-012-0471-7"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","volume":"31(2)","author":"Anastasi,E.","year":"2010","unstructured":"Anastasi,E.; Marchei,GG.; Viggiani,V.; Gennarini,G.; Frati,L.; Reale,MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010; 31(2): 113-9. http:\/\/dx.doi.org\/10.1007\/s13277-009-0015-y PMID: 20358424","journal-title":"Tumour Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","volume":"110(3)","author":"Havrilesky,LJ.","year":"2008","unstructured":"Havrilesky LJ, Whitehead CM, Rubatt JM.;et al. Evaluation of biomarker panels for early stage ovarian cancer detection and mo-nitoring for disease recurrence. Gynecol Oncol. 2008; 110(3): 374-82. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2008.04.041 PMID: 18584856","journal-title":"Gynecol Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1148\/radiol.2232011081","volume":"223(2)","author":"Coakley,FV.","year":"2002","unstructured":"Coakley FV, Choi PH, Gougoutas CA.;et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology. 2002; 223(2): 495-9. http:\/\/dx.doi.org\/10.1148\/radiol.2232011081 PMID: 11997559","journal-title":"Radiology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12032-017-1026-y","volume":"34(9)","author":"Capriglione,S.","year":"2017","unstructured":"Capriglione S, Luvero D, Plotti F.;et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challen-ge? A systematic review of literature. Med Oncol. 2017; 34(9): 164. http:\/\/dx.doi.org\/10.1007\/s12032-017-1026-y PMID: 28825178","journal-title":"Med Oncol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12885-015-1028-0","volume":"15","author":"Brennan,DJ.","year":"2015","unstructured":"Brennan DJ, Hackethal A, Mann KP.;et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer. 2015; 15: 33. http:\/\/dx.doi.org\/10.1186\/s12885-015-1028-0 PMID: 25655024","journal-title":"BMC Cancer"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30(5)","author":"Colombo,N.","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A.;et al. ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO con-sensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tu-mours and recurrent disease. Ann Oncol. 2019; 30(5): 672-705. http:\/\/dx.doi.org\/10.1093\/annonc\/mdz062 PMID: 31046081","journal-title":"Ann Oncol"},{"key":"ref=53","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guide-lines) . Ovarian Cancer (Version 22019)  National Comprehensive Cancer Network 2019https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf [18\/11\/2019];"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejogrb.2018.10.008","volume":"231","author":"Huang,J.","year":"2018","unstructured":"Huang,J.; Chen,J.; Huang,Q. Diagnostic value of HE4 in ovarian cancer: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018; 231: 35-42. http:\/\/dx.doi.org\/10.1016\/j.ejogrb.2018.10.008 PMID: 30317143","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejogrb.2012.10.036","volume":"167(1)","author":"Lin,J.","year":"2013","unstructured":"Lin,J.; Qin,J.; Sangvatanakul,V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ova-rian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013; 167(1): 81-5. http:\/\/dx.doi.org\/10.1016\/j.ejogrb.2012.10.036 PMID: 23228410","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1097\/IGC.0b013e318263efa2","volume":"22(7)","author":"Wu,L.","year":"2012","unstructured":"Wu,L.; Dai,ZY.; Qian,YH.; Shi,Y.; Liu,FJ.; Yang,C. Diagnostic value of serum human epididymis protein 4 (HE4)  in ovarian carcinoma: a systematic review and meta-analysis. Int J Gynecol Cancer. 2012; 22(7): 1106-12. http:\/\/dx.doi.org\/10.1097\/IGC.0b013e318263efa2 PMID: 22854652","journal-title":"Int J Gynecol Cancer"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"e17059","DOI":"10.1200\/JCO.2017.35.15_suppl.e17059","volume":"35(15_suppl)","author":"Lamy,PJ.","year":"2017","unstructured":"Lamy PJ, Touraine C, Mollevi C.;et al. Kinetics of HE4 and CA125 markers in metastatic ovarian cancer: The META4 study. J Clin Oncol. 2017; 35(15_suppl): e17059-9","journal-title":"J Clin Oncol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40644-019-0215-7","volume":"19(1)","author":"Laasik,M.","year":"2019","unstructured":"Laasik M, Kemppainen J, Auranen A.;et al. Behavior of FDG-avid supradiaphragmatic lymph nodes in PET\/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study. Cancer Imaging. 2019; 19(1): 27. http:\/\/dx.doi.org\/10.1186\/s40644-019-0215-7 PMID: 31142357","journal-title":"Cancer Imaging"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1010428317691189","DOI":"10.1177\/1010428317691189","volume":"39(2)","author":"Vallius,T.","year":"2017","unstructured":"Vallius T, Hynninen J, Auranen A.;et al. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer. Tumour Biol. 2017; 39(2): 1010428317691189. http:\/\/dx.doi.org\/10.1177\/1010428317691189 PMID: 28218038","journal-title":"Tumour Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14(9)","author":"Siravegna,G.","year":"2017","unstructured":"Siravegna,G.; Marsoni,S.; Siena,S.; Bardelli,A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14(9): 531-48. http:\/\/dx.doi.org\/10.1038\/nrclinonc.2017.14 PMID: 28252003","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20(2)","author":"Heitzer,E.","year":"2019","unstructured":"Heitzer,E.; Haque,IS.; Roberts,CES.; Speicher,MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019; 20(2): 71-88. http:\/\/dx.doi.org\/10.1038\/s41576-018-0071-5 PMID: 30410101","journal-title":"Nat Rev Genet"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16(7)","author":"Pantel,K.","year":"2019","unstructured":"Pantel,K.; Alix-Panabi\u00e8res,C. Liquid biopsy and minimal residual disease-latest advances and implications for cure. Nat Rev Clin Oncol. 2019; 16(7): 409-24. http:\/\/dx.doi.org\/10.1038\/s41571-019-0187-3 PMID: 30796368","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145754","author":"Pereira,E.","unstructured":"Pereira E, Camacho-Vanegas O, Anand S.;et al. Personalized circu-lating tumor dna biomarkers dynamically predict treatment respon-se and survival in gynecologic cancers. PLoS One. 2015; 10(12) e0145754 http:\/\/dx.doi.org\/10.1371\/journal.pone.0145754 PMID: 26717006","journal-title":"PLoS One"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","volume":"35(12)","author":"Christie,EL.","year":"2017","unstructured":"Christie,EL.; Fereday,S.; Doig,K.; Pattnaik,S.; Dawson,SJ.; Bowtell,DDL. Reversion of brca1\/2 germline mutations detected in circula-ting tumor dna from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017; 35(12): 1274-80. http:\/\/dx.doi.org\/10.1200\/JCO.2016.70.4627 PMID: 28414925","journal-title":"J Clin Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","author":"Bettegowda,C.","unstructured":"Bettegowda C, Sausen M, Leary RJ.;et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014; 6(224) 224ra24 http:\/\/dx.doi.org\/10.1126\/scitranslmed.3007094 PMID: 24553385","journal-title":"Sci Transl Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","volume":"25(8)","author":"Baumgartner,JM.","year":"2018","unstructured":"Baumgartner JM, Raymond VM, Lanman RB.;et al. Preoperative circulating tumor dna in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival. Ann Surg Oncol. 2018; 25(8): 2400-8. http:\/\/dx.doi.org\/10.1245\/s10434-018-6561-z PMID: 29948422","journal-title":"Ann Surg Oncol"},{"key":"ref=67","doi-asserted-by":"publisher","author":"Asante,DB.","unstructured":"Asante,DB.; Calapre,L.; Ziman,M.; Meniawy,TM.; Gray,ES. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? Cancer Lett. 2020; 468: 59-71. http:\/\/dx.doi.org\/10.1016\/j.canlet.2019.10.014 PMID: 31610267","DOI":"10.1016\/j.canlet.2019.10.014"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001216","author":"Altman,DG.","unstructured":"Altman,DG.; McShane,LM.; Sauerbrei,W.; Taube,SE. Reporting recommendations for tumor marker prognostic studies (remark): explanation and elaboration. PLoS Med. 2012; 9(5) e1001216 http:\/\/dx.doi.org\/10.1371\/journal.pmed.1001216 PMID: 22675273","journal-title":"PLoS Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162(1)","author":"Moons,KG.","year":"2015","unstructured":"Moons KG, Altman DG, Reitsma JB.;et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Di-agnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015; 162(1): W1-73. http:\/\/dx.doi.org\/10.7326\/M14-0698 PMID: 25560730","journal-title":"Ann Intern Med"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155(8)","author":"Whiting,PF.","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME.;et al. QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8): 529-36. http:\/\/dx.doi.org\/10.7326\/0003-4819-155-8-201110180-00009 PMID: 22007046","journal-title":"QUADAS-2:arevised tool for the quality assessment of diagnostic accuracy studies.Ann Intern Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jrsm.1313","volume":"14","author":"Zhang,Y.","year":"2018","unstructured":"Zhang,Y.; Akl,EA.; Sch\u00fcnemann,HJ. Using systematic reviews in guideline development: the GRADE approach. Res Synth Methods. 2018; 14: 1313. http:\/\/dx.doi.org\/10.1002\/jrsm.1313 PMID: 30006970","journal-title":"Res Synth Methods"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T18:07:04Z","timestamp":1603476424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181328\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,7,28]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666200425211732","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}